Lutetium-177 PSMA Therapy, or Prostate-Specific Membrane Antigen Therapy, is treatment that is increasingly being used for people with advanced prostate cancer. Lu177 PSMA therapy aims to reduce the size of the tumor and stop them from multiplying, also to ease the symptoms and pain related to bone metastases. It is most often used when the disease has metastasised and when other therapies are poorly tolerated or have failed.
How Does Lutetium-177 PSMA Therapy Work?
PSMA is a type of protein located on the surface of a cell and is naturally found on the prostate gland. In someone with prostate cancer, an increased amount of PSMA cell surface receptor is over expressed. If the prostate cancer has spread to other parts of the body , the PSMA will also appear in those areas. Lutetium-177 PSMA Therapy uses a molecule which attaches itself to the PSMA receptors on the cancer cells. the PSMA molecule is bound with Lutetium-177, which emits beta radiation, a destructive type of radiation that damages the cancer cells. The PSMA molecule acts as a means of transporting the radiation to the tumor site, so that the whole body does not get exposed to the radiation. This is often referred to as Peptide Receptor Radionuclide Therapy (PRRT).